NovAccess Global Inc. (XSNX)
| Market Cap | 18.57K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.89M |
| Shares Out | 61.91M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 181 |
| Average Volume | 1,041 |
| Open | 0.0003 |
| Previous Close | 0.0003 |
| Day's Range | 0.0003 - 0.0003 |
| 52-Week Range | 0.0002 - 0.0190 |
| Beta | 2.45 |
| RSI | 43.48 |
| Earnings Date | Feb 7, 2025 |
About NovAccess Global
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio. [Read more]
Financial Performance
Financial StatementsNews
NovAccess Global Advisory on Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its A...
NovAccess Global Announces New License to Advance its Immunotherapy Platform
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous syste...
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de...
NovAccess Global Announces $10.7 Million Financing
Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company develop...
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. Event: December 7th ...
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app...
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS Tumors Potential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology Market CLEVELAND, OH...
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv...
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a...
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Prec...
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain Tumors Recent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at...
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award CLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company develop...
NovAccess Global to Present at World Orphan Drug Congress
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dw...
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his Contributions CLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical co...
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company's Lead Scientist and President of its StemVax Therapeutics Division
Topic: Immunotherapy Advantages Over Surgical Treatment CLEVELAND, OH / ACCESSWIRE / January 5, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for bra...
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support Networks CLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biome...
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of ...
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1 FDA Expands the Scope of the Company's Submission Accelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CL...
NovAccess Global Announces Fireside Chat with Board Member Perspectives
Topic: Opportunities for the Biomedical Field and for Shareholders CLEVELAND, OH / ACCESSWIRE / October 20, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunothera...
NovAccess Global Announces Fireside Chat Series for the Investment Community
CLEVELAND, OH / ACCESSWIRE / September 29, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that it will be co...
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
Includes 7.5 Million Shares for Innovest Global Share Distribution Increases Unaffiliated Float While Significantly Expanding Shareholder Base CLEVELAND, OH / ACCESSWIRE / September 22, 2022 / NovAcce...
NovAccess Global Announces Uplisting to OTCQB
CLEVELAND, OH / ACCESSWIRE / August 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the trading of i...
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
This corrects the release that ran earlier today, replacing the name of the executive quoted in the press release and other minor edits. Accelerating on the Path Toward Immunotherapy for Glioblastoma ...
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CLEVELAND, OH / ACCESSWIRE / July 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX), a biomedical company developing novel ...
NovAccess Global CEO Dwain Irvin Featured on MoneyTV
CLEVELAND, OH / ACCESSWIRE / June 14, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin was a featured guest on MoneyTV, an internationally-syndic...